COPD

London, UK (October, 19 - 20, 2015 )

COPD causes 6% of the world’s morbidity and costs the worldwide economy $36 billion and though non curable, it can be tamed through a range of management mechanisms. In recent years there have been large advances in proteomics and transcriptomics which have allowed for the development of personalised treatment plans developed for the precise comorbidity.

Now in its 7^th year, COPD 2015 will gather a global audience of respiratory experts and scientific pioneers to discuss the latest developments in combinational therapies, new drugs and personalised treatment as well as the challenges of clinical trials. Join us as we ask questions such as: How does one reliably recruit and run clinical trials in a disease that branches to such extremes? What is the correct phenotype to measure in the disease? With the majority of COPD patients on varying courses of polypharmacy due to a range of different debilitating diseases alongside COPD – how can one find a clean patient? Plus much more!

Our understanding of the pathophysiology in COPD has increased dramatically thanks to developments in the area of network biology. By understanding the complicated mechanisms by which different aspects of the disease interact it is possible to intervene with crucial nodes progressing the disease. Discussions will be opened on the various models of network biology and biomarkers of the disease to gain a greater understanding of this multifaceted disease.

Featured speakers Include:

·         Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG

·         Philip Silkoff, Senior Medical Director, Johnson and Johnson Pharmaceutical Services LLC

·         Stefano Petruzzelli, Chief Medical Officer and Director, Global Clinical Development, Chiesi Farmaceutici S.p.A

·         Sanjeeva Dissanayake, Head of Medical Sciences – Respiratory, Mundipharma

·         Noel Snell, Director of Research, British Lung Foundation

·         Geoff Down, Chief Medical Officer, Prosonix

·         Konstantinos Kostikas, Medical Director Respiratory COPD Region Europe, Novartis Pharma

·         Thomas Schlange, Senior Biomarker Expert, Bayer

·         Matthew Sleeman, Senior Director of Biology, Respiratory, Inflammation and Autoimmunity, MedImmune

Benefits of attending:

·         Discuss  the advantages and disadvantages of combinational therapeutics

·         Gain insight into formulation developments and the manufacturing of dry powder inhalation products

·         Evaluate COPD and comorbidities

·         Review the challenges in clinical trial designs and in drug development

·         Learn about "first in class" inhaled drugs for the treatment of COPD and cystic fibrosis

·         Ascertain the ACOS Definition and characteristics of a grey-zone syndrome, excluded from current asthma and COPD trials

·         Explore  recent advances made in COPD biomarkers

·         Study the role of lymphoid follicles in COPD Novel delivery and formulation methods

·         Analyse airway disease endotyping for personalized therapeutics

We look forwards to welcoming you to the 7th Annual COPD Conference 2015 taking place in central London on the 15th-16th October 2015.

Více: http://www.copd-conference.co.uk/gate2biotech